


## Normal Global Strain and Strain Rate by Age 242 Patients in Cleveland, Brisbane, and Aachen





### From the Chamber Quantification Guideline

ASE American Society of Echocardiography


**Recommendations.** LV systolic function should be routinely assessed using 2DE or 3DE by calculating EF from EDV and ESV. LV EFs of <52% for men and <54% for women are suggestive of abnormal LV systolic function. Two-dimensional STE-derived GLS appears to be reproducible and feasible for clinical use and offers incremental prognostic data over LV EF in a variety of cardiac conditions, although measurements vary among vendors and software versions. To provide some guidance, <u>a peak GLS in the range of -20% can</u> <u>be expected in a healthy person, and the lower the absolute value</u> of strain is below this value, the more likely it is to be abnormal.

- GLS below -16% is abnormal in most circumstances
- Between -16% and -17% borderline
- It's a continuum so cut-offs are less meaningful



















Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors The EACVI/ASE Inter-Vendor Comparison Study											
Konstantinos E. Farsalinos, MD, Ana M. Daraban, MD, Serkan Ünlü, MD, James D. Thomas, MD, PhD, Luigi P. Badano, MD, PhD, and Jens-Uwe Voigt, MD, PhD, Leuven, Belgium; Chicago, Illinois; and Padua, Italy											
	One week:	22nd - 26th April 2013, Leuven									
	7 machines:	Esaote GE Hitachi-Aloka Philips Samsung Siemens Toshiba	MyLab Alpha Vivid E9 Prosound Alpha7 CV iE 33 EKO 7 SC 2000 Artida								
	2 independent softwares:	Epsilon Tomtec	Echolnsight Image Arena								
JASE 2015; 28: 1171-81											











### 93356: New add-on CPT code for strain Strain has been a Category III (tracking) code for several years


Now announced as Category I (reimbursable) as of 1/1/2020


H	Private office Non-Facility									
	CY2020 wRVU	CY2020 Payment	CY2020 PE RVU	CY2020 Payment	CY2020 MPI	CY2020 Payment	CY2020 Total RVU	CY2020 Payment		
+93556 Myocrd strain img spckl trck	0.24	\$ 8.66	<mark>0.87</mark>	<mark>\$ 31.40</mark>	0.02	\$ 0.72	1. 13	\$ 40.78		
		Hospital OPD Facility								
	CY2020 wRVU	CY2020 Payment	CY2020 PE RVU	CY2020 Payment	CY2020 MPI	CY2020 Payment	CY2020 Total RVU	CY2020 Payment		
+93556 Myocrd strain img spckl trck	0.24	\$ 8.66			0.01	\$ 0.36	0. 25	\$ 9.02		
PE not reimbursed in HOPD yet, but bill, so you can support higher APC in future										
















# <section-header><section-header><section-header><section-header><image><text><text><text><list-item><list-item>


<section-header><image><section-header><section-header><section-header><section-header><section-header><section-header><section-header><image>


35


## <section-header><section-header><section-header><section-header><section-header><section-header><text><section-header><text><text>

















































































































































Studies/First Author (Ref. #)	Sensitivity	Specificity	PPV	NPV
Fallah-Rad et al. (44)*				
2% absolute (10.1% relative) decrease in LS	79%	82%	60%	92%
0.8% decrease in RS	86%	81%	60%	95%
Sawaya et al. (41)†				
10% decrease in GLS	78%	79%	50%	93%
Elevated hsTnl	67%	82%	50%	90%
10% decrease in GLS and elevated hsTn1	55%	97%	83%	89%
10% decrease in GLS or elevated hsTnl	89%	65%	40%	97%
Sawaya et al. (40)†				
GLS <19%	74%	73%	53%	87%
hsTnl >30 pg/ml	48%	73%	44%	77%
LS <19% and usTnl >30 pg/ml	35%	93%	67%	77%
LS <19% or usTnl >30 pg/ml	87%	53%	43%	91%
Negishi et al. (42);				
11% reduction in global GLS	65%	95%	-	
3.6% reduction in global GLSR early diastole	82%	67%		-
6.4% reduction in global GLSR	73%	67%	-	-
Absolute GLS at 6 months <-20.5%	96%	66%		







## What is the Role of Strain After Completion $\bigotimes ASE$ Aretean Society of Anti-Cancer Therapy?






























## CAD by Coronary Artery Distribution





Apex strain > 2x Rest of heart


- Territorial analyses to assess CAD by coronary artery distribution.
- Lower absolute regional GLS in the LAD distribution detected CAD with 91% sensitivity and 45% specificity.
- Decreased absolute GLS in the RCA CAD with 79% sensitivity and 76% specificity.


Phelan, Collier et al. Heart 2012; 98: 1442-1448





























































































```
143
```






## ORIGINAL ARTICLE

Relative 'apical sparing' of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis

Dermot Phelan, Patrick Collier, Paaladinesh Thavendiranathan, Zoran B Popović, Maze<u>n Hanna, Juan Carlos Plana, Thomas H Marwick, James D Thomas</u>





Phelan, Collier et al. Heart 2012; 98: 1442-1448

